Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
malaria vaccine 257049 + AS01B is a combination product comprised of the malaria vaccine candidate "257049", which is synonymous with the RTS,S antigen, formulated together with the AS01B adjuvant system. The RTS,S antigen is a recombinant protein targeting the circumsporozoite protein (CSP) of *Plasmodium falciparum*, aiming to elicit both humoral and cellular immune responses. AS01B is a liposome-based adjuvant that combines 3-*O*-desacyl-4'-monophosphoryl lipid A (MPL) and the saponin QS-21 to enhance the immune response by stimulating innate immunity, leading to strong and persistent CSP-specific antibody and T cell responses. The combination has been developed for the prevention of *Plasmodium falciparum* malaria, with clinical trials conducted primarily in children and infants in malaria-endemic regions[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on malaria vaccine 257049 + AS01B.